Sorbitol

證據等級: L5

預測適應症: 1 個

Sorbitol: From Osmotic Agent to Exercise-Induced Malignant Hyperthermia

One-Sentence Summary

Sorbitol is a sugar alcohol widely used as an osmotic laxative, humectant, and pharmaceutical excipient; no formal approved indication is recorded in the Dutch regulatory database. The TxGNN model predicts it may be effective for Exercise-Induced Malignant Hyperthermia, however with 0 clinical trials and 0 publications currently supporting this direction, the evidence base consists entirely of a computational model prediction.

Quick Overview

Item	Content
Original Indication	No approved indication on record
Predicted New Indication	Exercise-induced malignant hyperthermia
TxGNN Prediction Score	99.40%
Evidence Level	L5
NL Market Status	Not Registered
Number of Authorizations	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available for Sorbitol in this evidence pack. Based on established pharmacology, Sorbitol is an osmotic sugar alcohol that exerts its primary therapeutic effect through osmotic pressure regulation in the gastrointestinal tract. Its metabolic pathway — Sorbitol → Fructose → glycolysis — is well characterised in intermediary metabolism but carries no known direct pharmacological relevance to skeletal muscle pathophysiology.

Exercise-induced malignant hyperthermia is a rare, potentially life-threatening disorder caused predominantly by gain-of-function mutations in the RYR1 gene, which encodes the ryanodine receptor governing calcium release from the sarcoplasmic reticulum of skeletal muscle. During an acute episode, uncontrolled intracellular calcium efflux leads to sustained muscular contraction, severe hyperthermia, and metabolic acidosis. The established first-line treatment is dantrolene, which directly suppresses RYR1-mediated calcium release — a completely different mechanism from osmotic modulation.

There is no recognised mechanistic bridge between Sorbitol’s osmotic properties and RYR1-mediated calcium dysregulation. The high TxGNN score (0.994) most plausibly reflects indirect node proximity in the knowledge graph through shared skeletal muscle metabolism pathways, rather than a true drug–disease pharmacological connection. This prediction is assessed as a likely computational false positive with no current clinical translational basis, and should not be advanced without preclinical mechanistic evidence.

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

Currently no related literature available.

Netherlands Market Information

Sorbitol currently holds no marketing authorisation registered with the CBG-MEB (College ter Beoordeling van Geneesmiddelen) in the Netherlands. There are no RVG-numbered products on record. Should future evidence warrant regulatory consideration, a new marketing authorisation application or extension of indication procedure would be required from the outset.

Safety Considerations

Please refer to the SmPC (Summary of Product Characteristics) for safety information. As no products are currently registered in the Netherlands, the relevant reference documents would be those from comparable jurisdictions (e.g., EMA-authorised products containing Sorbitol as an active substance).

Conclusion and Next Steps

Decision: Hold

Rationale: This repurposing candidate is classified as L5 (model prediction only) — there are no registered clinical trials, no published literature, and no established mechanistic link between Sorbitol’s osmotic pharmacology and the RYR1-driven calcium dysregulation underlying exercise-induced malignant hyperthermia. The prediction is assessed as a likely knowledge-graph false positive.

To proceed, the following is needed:

Retrieve formal MOA documentation for Sorbitol via DrugBank API to rule out any overlooked secondary pharmacology
Establish a plausible mechanistic hypothesis connecting Sorbitol to RYR1-mediated calcium handling (e.g., osmotic effects on intracellular calcium dynamics, or fructose-pathway interactions with muscle energetics)
Generate at minimum Level L4 evidence: in vitro or animal model data demonstrating any meaningful effect on malignant hyperthermia pathways
If preclinical evidence emerges, initiate CBG-MEB pre-submission consultation — noting that no NL market presence currently exists and a full authorisation pathway would be required
Conduct a competitive landscape review against dantrolene and other RYR1-targeted agents to assess clinical differentiation potential
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.